Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15998983 | 0.90 | RECQL (0.54) | RECQLALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL15997842 | 0.85 | RECQL (0.49) | RECQLALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL15687379 | 0.84 | RECQL (0.48) | RECQLALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL30729366 | 0.84 | BRD4 (0.49) | RECQLALDH1A1KDM4EPTGER4PKM | |
| SCHEMBL25966967 | 0.80 | ALDH1A1 (0.49) | RECQLALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL15999090 | 0.79 | USP2 (0.46) | RECQLALDH1A1KDM4EHSD17B10PKM | |
| SCHEMBL1169685 | 0.77 | RECQL (0.60) | RECQLALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4792406 | 0.77 | RECQL (0.60) | RECQLALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL1169734 | 0.77 | RECQL (0.60) | RECQLALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL15997707 | 0.77 | LMNA (0.45) | RECQLALDH1A1LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101654-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, MAPKAP1, PIK3R5 | RECQL 3871/4885ALDH1A1 3791/4885LMNA 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.